UNASSIGNED: IgA @entity8 leads young @entity1 to dialysis more often than other @entity8 , because often diagnosis and therapy are made late. Nephrologists waive to treat @entity6994 pts with chronic @entity177 , believing that treatment may not be effective and safe. Moreover, studies in @entity6994 pts with @entity177 are lacking. Small studies seem to indicate a possible utility of RAS blockers and @entity288 in these @entity1 . Recently, VALIGA study showed that @entity288 and immunosuppressants were more frequently used in pts with @entity470 <30  ml/min than in those with @entity470 >30  ml/min (60 vs. 44  %, respectively; p  =  0.004). The goal of treating @entity6994 pts is to obtain a time-average @entity644 <1  g/day, regardless of the degree of renal function and histological damage. RASB and @entity288 seem to be able to obtain this result. However, it's important to pay attention to the appearance of adverse events of CS. In the literature, major side effects occurred in 29 of 463 (6.2  %) @entity1 enrolled in RCTs. However, scarce informations are obtained about the safety of CS in @entity1 with @entity177 . To better evaluate this aspect, we considered three studies, that used similar schemes of therapy and included @entity1 with different degrees of renal function (1: GFR 90  ml/min/1.73  m(2), 2: 81  ml/min/1.73  m(2), 3: 34  ml/min/1.73  m(2)). The occurrence of adverse events increased with the worsening of renal function (2.3, 5.7 and 15.4  % in studies 1, 2 and 3 respectively). The aim of the treatment for a @entity1 with an @entity470 <30 is to slow the progression and to delay the need for dialysis. Therefore, in stage CKD 2, 3 and 4 with a @entity644 >1  g/day a 6-month course of @entity288 could be useful and safe.

Treatment of XXXX with @entity177 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'people'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity8 :: ('MESH:D007674', 'Disease') :: ['glomerular diseases', 'Nephropathy'] @entity470 :: ('1956', 'Gene') :: ['eGFR'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency', 'reduced renal function'] @entity6994 :: ('60498', 'Gene') :: ['IgAN'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity8 :: (MESH:D007674,Disease) :: ['IgA nephropathy']
